ZURA
NASDAQ HealthcareZura Bio Limited - Class A Ordinary shares
Biotechnology
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
�� 市场数据
| 价格 | $5.81 |
|---|---|
| 成交量 | 718,069 |
| 市值 | 551.26M |
| 贝塔系数 | 0.240 |
| RSI（14日） | 45.9 |
| 200日均线 | $4.02 |
| 50日均线 | $6.18 |
| 52周最高 | $7.44 |
| 52周最低 | $0.98 |
| Forward P/E | -58.10 |
| Price / Book | 4.22 |
🎯 投资策略评分
ZURA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (51/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🎈 Over-Hyped (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ZURA in your text
粘贴任何文章、记录或帖子 — 工具将提取 ZURA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.